The new members of Peregrine’s incubator will also include esteemed institutional leaders - Tel Aviv University, Ben-Gurion University of the Negev, and Shaare Zedek Medical Center.
Following Peregrine’s consecutive win of the Israel Innovation Authority’s incubators tender, the consortium will jointly develop and invest in medical start-ups. The Israel Innovation Authority will also match up to 85% of each early-stage investment by Incentive over the next eight years.
The incubator is utilized as an anchor for developing new ventures and supporting pre-seed, seed, and early-stage investments, the incubator leverages Peregrine’s decades of experience and substantial investments to guide young life science companies through the early phases of development. This growth is fed by Peregrine’s various dedicated investment vehicles designed to support life sciences technologies in different stages of development, from pre-seed to late growth to pre-IPO companies and everything in between.
The incubator’s unique model has yielded extraordinary results to date. Notably, of the 60 companies that were established in the incubator, 34 of them remain active companies. The aggregate value of companies that have graduated from Incentive Incubator has reached the $5 billion mark.
